Tiziana Life Sciences Ltd. (TLSA) intrinsic value & 10-year financials
Tiziana Life Sciences Ltd. (TLSA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2024)
- —
- ROIC (10-yr avg)
- 443.4%
- Free cash flow (FY2024)
- -$1.5M
TLSA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$11.9M | -$0.11 | -$1.5M | — | — |
| FY2023 | — | -$17.7M | -$0.17 | — | — | — |
| FY2022 | — | -$15.4M | -$0.15 | — | — | — |
| FY2021 | — | -$23.4M | -$0.24 | -$21.8M | — | — |
| FY2020 | — | -$26.1M | -$0.16 | -$11.3M | — | 607.0% |
| FY2019 | — | -$9.3M | -$6.83 | -$6.8M | — | 186.9% |
| FY2018 | — | -$8.0M | -$6.27 | — | — | 244.4% |
| FY2017 | — | -$8.7M | -$8.59 | -$7.5M | — | 499.2% |
| FY2016 | — | -$9.8M | -$11.35 | — | — | 679.5% |
| FY2015 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Tiziana Life Sciences Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Tiziana Life Sciences Ltd has historically struggled to out-earn its cost of capital, averaging just 4.4% ROIC.
Tiziana Life Sciences Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Tiziana Life Sciences Ltd is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.